Bli medlem
Bli medlem

Du är här


Bionor Pharma ASA : Minutes from the Extraordinary General Meeting 7 November 2016

(Oslo, Norway, 8 November 2016) The Extraordinary General Meeting of Bionor
Pharma ASA (OSE:BIONOR) yesterday adopted all items and resolutions as
proposed in the notice.

The Extraordinary General Meeting approved the board authorization to increase
the share capital.

The minutes of the Extraordinary General Meeting is attached hereto.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Further information
Unni Hjelmaas, Acting CEO, +47 915 19 651,
Jens Krøis, CFO, +45 208 01 668,

About Bionor
Bionor Pharma's mission is to enable the immune system to fight HIV infection.
Bionor is the first company, which has successfully completed a clinical
trial using the shock and kill approach, thereby creating a strong foundation
for further advancing its therapeutic vaccine Vacc-4x in combination with
other agents towards a functional cure. The company believes it has first
mover potential based on clinical results to date and early adoption of the
shock and kill strategy. In December 2015, Bionor announced that the HIV
trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint
by reducing latent HIV reservoir and further demonstrated control of viral
load. Bionor currently retains full ownership rights to the HIV immunotherapy
Vacc-4x, i.e., the upside potential from partnering or licensing remains with
the company's shareholders.

Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is
available at


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.